Selected articles
Articles for label Divišová Kristýna are displayed.. Show all articles
Treatment of patients with metastatic urothelial cancer „unfit“ for cisplatin treatment
03/2019 MUDr. Kristýna Divišová; MUDr. Jana Katolická, Ph.D.; MUDr. Milan Kohoutek
Cisplatin-based chemotherapy is the standard first-line treatment in advanced urothelial cancers. However, more than 50 % of patients are not eligible for cisplatin. Urothelial cancer patients are of higher median age and often present with organ impairment and comorbidities. In frail patients, recommended treatment options include carboplatin or gemcitabine monotherapy, or GCa or imunotherapy if possible.
ENTIRE ARTICLE
Cisplatin-based chemotherapy is the standard first-line treatment in advanced urothelial cancers. However, more than 50 % of patients are not eligible for cisplatin. Urothelial cancer patients are of higher median age and often present with organ impairment and comorbidities. In frail patients, recommended treatment options include carboplatin or gemcitabine monotherapy, or GCa or imunotherapy if possible.